Non-invasive neuromodulation × neurological and psychiatric conditions

Filters
Show labels ◆

✥ Click and hold to pan the map; scroll wheel and trackpad work too.

Certainty of evidence (colour)
Size
Device label
◆ at least one stimulator with an FDA or CE label for this condition (switch FDA or CE on at the top to dim all other cells)
Guideline level
A definite · B probable · C possible efficacy (IFCN/EAN-type rating); − = level reached for lack of efficacy; FDA = cleared device
How this map was built

Volume. ClinicalTrials.gov API v2: interventional studies matching the condition and intervention terms. PubMed E-utilities: title/abstract matches, all records, filtered to randomized controlled trial[pt], and to systematic review[pt] OR meta-analysis[pt]. Open a cell to reach the exact live query.

Trending. Publication momentum uses relative growth rate, CAGR and doubling time (standard scientometric growth indicators), comparing 2020–22 with 2023–25 and normalising to growth of all of PubMed (+4%). Trial momentum compares interventional trial starts in the same windows against all ClinicalTrials.gov starts (+13%). ▲ Trending = publications growing ≥1.25× faster than PubMed (≥10 recent records) or trial starts ≥1.5× faster than the registry (≥5 recent trials). ★ Promising = regulatory or guideline signals of expected benefit since 2024 (FDA Breakthrough designation, new FDA/CE labels, G-BA finding of "Potenzial", guideline upgrades) or a recent positive meta-analysis. ✕ marks recent negative pivotal trials or guideline recommendations against. The score is a screening aid, not an efficacy estimate.

Certainty. Graded per cell from the IFCN rTMS guideline (Lefaucheur 2020), the tDCS guidelines (Lefaucheur 2017; Fregni 2021), Cochrane reviews and the most recent meta-analyses found. Where a GRADE rating was published it is used; otherwise the rating is an indicative judgement from the synthesis literature.

Read with care
  • Indicative scoping map, not a systematic review or formal GRADE assessment.
  • Counts are not de-duplicated or quality-filtered and overlap across modality columns (theta burst sits inside rTMS; deep TMS is a subset of TMS). Keyword matches include mechanistic and healthy-volunteer studies.
  • The biofeedback column includes EMG, thermal and HRV biofeedback, not only EEG neurofeedback. The taVNS column includes cervical nVNS (gammaCore). Implanted VNS, DBS and SCS are out of scope, as is ablative MR-guided focused ultrasound; the TUS / TPS column covers only low-intensity ultrasound and transcranial pulse stimulation.
  • Broad keyword sets inflate some rows: Alzheimer / MCI includes all dementia; Addiction includes smoking and craving studies; Eating disorders includes obesity; Vestibular counts are dominated by generic dizziness and vertigo, while PPPD and MdDS data are pilot-scale.
  • Fatigue / Post-COVID uses a proxy evidence base: most trials address MS-, cancer- or stroke-related fatigue; Post-COVID-specific data are pilot-scale.
  • Pain (split 14 Oct 2026, counts pulled that day): Neuropathic pain counts neuropathic, central, post-stroke, phantom, trigeminal and postherpetic pain and painful polyneuropathy; Fibromyalgia / nociplastic counts fibromyalgia, nociplastic, chronic widespread and chronic primary pain. Unspecified chronic pain (e.g. chronic low back pain) is no longer counted. CRPS statements are filed under nociplastic, following ICD-11 (chronic primary pain).
  • Stroke – motor: PubMed restricted to motor/gait outcomes. Post-stroke dysphagia: ClinicalTrials.gov counts cover dysphagia of any cause. On ClinicalTrials.gov both stroke rows use broader terms.
  • Pudendal neuralgia (added 8 Oct 2026, counts pulled that day) uses a narrow query (pudendal neuralgia or entrapment, Alcock canal syndrome). Brain-stimulation trials in chronic pelvic pain in general (endometriosis, bladder pain, CP/CPPS, vulvodynia) are not counted; a 2026 systematic review found 15 such studies with inconsistent results.
  • TENS / peripheral (added 9 Oct 2026, counts pulled 8–9 Oct 2026) covers surface TENS, transcutaneous tibial nerve stimulation and repetitive peripheral magnetic stimulation. Percutaneous tibial stimulation, NMES/FES, interferential therapy and cranial electrotherapy are not counted. Keyword matches are broad: in Depression and Fatigue most hits are pain or cancer trials with secondary outcomes.
  • Restless legs (RLS) (added 18 Oct 2026, counts pulled that day): transcutaneous spinal direct current stimulation (tsDCS) is rated in the tDCS row and bilateral high-frequency peroneal nerve stimulation (TOMAC, Nidra) in the TENS / peripheral row, but the row queries do not match either. Supplementary counts with dedicated queries: tsDCS 7 PubMed records (2 RCTs, 0 registered trials); TOMAC 22 records (3 RCTs, 6 registered trials). Raw row counts contain false positives: the rTMS RCT count includes a tsDCS trial that used TMS only as an outcome measure, and one registered taVNS trial also matches the TENS query.
  • Volume does not imply benefit. Several large cells (neurofeedback in ADHD, tDCS in stroke) show many trials with low certainty or null blinded outcomes.